Ken Griffin Maxcyte, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Maxcyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,700 shares of MXCT stock, worth $27,405. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,700
Previous 1,000
770.0%
Holding current value
$27,405
Previous $3,000
1100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding MXCT
# of Institutions
123Shares Held
69.8MCall Options Held
8.7KPut Options Held
6K-
Cadian Capital Management, LP New York, NY9.34MShares$29.4 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$25.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.43MShares$17.1 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$15.9 Million18.06% of portfolio
-
Morgan Stanley New York, NY4.41MShares$13.9 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $320M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...